Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M. Hanefeld.
The metabolic syndrome: roots, myths, and facts.
The metabolic syndrome, pp. 13-24
[2.]
G.G.L. Biondi-Zoccai, A. Abbate, G. Liuzzo, L.M. Biasucci.
Atherothrombosis, inflammation, and diabetes.
J Am Coll Cardiology, 41 (2003), pp. 1071-1077
[3.]
H.F. Escobar-Morreale, G. Villuendas, J.I. Botella-Carretero, J. Sancho, J.L. San Millán.
Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women.
Diabetologia, 46 (2003), pp. 625-633
[4.]
M.O. Goodrazi, S. Erickson, S.C. Port, et al.
Relative impact of insulin resistance and obesity on cardiovascular risk factors in polycystic ovary syndrome.
Metabolism, 52 (2003), pp. 713-719
[5.]
E. Leinonen, E. Hurt-Camejo, O. Wiklund, L. Hulten, A. Hiukka, M.R. Taskinen.
Insulin resistance and adiposity correlate with acutephase reaction and soluble cell adhesion molecules in type 2 diabetes.
Atherosclerosis, 166 (2003), pp. 387-394
[6.]
S. Haffner, H. Taegtmeyer.
Epidemia obesity and the metabolic syndrome.
Circulation, 108 (2003), pp. 1541-1545
[7.]
J.F. Ascaso, P. Romero, J.T. Real, R.I. Lorente, J. Martínez-Valls, R. Carmena.
Abdominal adiposity (waist circumference) and its relation to insulin resistance and the metabolic syndrome in a south european population.
Eur J Intern Med, 14 (2003), pp. 101-106
[8.]
S. Haffner.
Insulin resistance, inflammation and the prediabetic state.
Am J Cardiol, 92 (2003), pp. 18-26
[9.]
J.M. Fernández-Real, A. López-Bermejo, R. Casamitjana, W. Ricart.
Novel interactions of Adiponectin with the endocrine system and inflammatory parameters.
Clin Endocr Metab, 88 (2003), pp. 2714-2718
Copyright © 2003. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.